Acrivon Therapeutics
Clinical trials sponsored by Acrivon Therapeutics, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug combo aims to shrink endometrial tumors Results expected May 2027 (estimated)
- New hope for advanced cancers: experimental drug ACR-2316 enters first human trial Results expected Aug 2027 (estimated)
-
New hope for advanced cancers: experimental drug ACR-2316 enters first human trial
Disease control Recruiting nowThis early-stage trial tests an experimental drug called ACR-2316 in 100 people with advanced solid tumors that have spread or come back. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. It is for patients who have had up to 3 pr…
Phase 1/2 • Sponsor: Acrivon Therapeutics • Aim: Disease control
Last updated Sep 21, 2026 13:01 UTC
-
New drug combo aims to shrink endometrial tumors
Disease control Recruiting nowThis Phase 2 trial tests an experimental drug called ACR-368, alone or with a low dose of gemcitabine, in 350 people with high-grade endometrial cancer. A special test (OncoSignature) helps decide which treatment arm a participant joins. The main goal is to see if the drug shrink…
Phase 2 • Sponsor: Acrivon Therapeutics • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC